Trial Profile
A Two-Part, Sequential Design Study to Determine Debio 0932 Absolute Oral Bioavailability, Mass Balance Recovery, Metabolite Profiling and Structural Identification in 3 Cohorts of Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2013
Price :
$35
*
At a glance
- Drugs RGRN-305 (Primary)
- Indications Lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Pharmacogenomic; Pharmacokinetics
- 03 Dec 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database
- 30 Oct 2012 New trial record